
April 1, 2008 -
Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) announced that Dr. Paul Tan, LCT CEO and Dr. Anil K. Anal, LCT Material Scientist, presented some data at a session on nanotechnology at the
NZBio 2008 Conference in Auckland, New Zealand. Their presentation showcased the company's proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell®, to be implanted without the use of toxic immune suppressive drugs.
On March 31, the Company reported positive early preliminary data from an on-going Phase I/IIa clinical trial which shows that following implant into patients with insulin dependent diabetes, the encapsulated porcine pancreatic islets remain functioning for at least 6 months and beneficial effects were greater than expected... LCT's Press Release -